whitepaper
Application note: Developing next-gen in vitro Huntington’s disease assays
The use of high-density MEAs to probe single cell and network activity electrophysiology of a hiPSC-derived Huntington’s disease model
List view / Grid view
Cell Line Development
article
Cell line development tactics and strategies for faster Investigational New Drug timelines
Complexities related to the development of stable cell lines and increased risk of contamination in upstream and downstream processes, have led many developers to seek critically needed expertise from external partners. Soojin Han, Samsung Biologics America, offers an expert look at the various challenges and tactics that can be applied.
article
Which CHO cell is the right CHO cell?
Dr Louis Boon offers guidance on how to select the best CHO cell for the upstream bioprocessing of biologics. He also explains how automation can aid monoclonality and why the most efficient approach during the development of biological drugs is to utilise an established cell line platform.
article
Recent trends in upstream bioprocessing and major challenges in process development
Aparajita Dubey summarises the recent trends in upstream bioprocessing and highlights the challenges and solutions involved in its process development.
article
Spotlighting data in upstream bioprocesses – a recipe for quick and successful cell lines
Upstream bioprocessing is the epicentre of biologics development, wherein scientists piece together a series of carefully chosen processes with contributing components and parameters to enable the production of highly effective biotherapeutics. Unjulie Bhanot explains why an effective data management system is vital in this quest for the next big therapeutic.
article
Cell line development – global market drivers, trends and its impact on improving biologics development from early phase to IND during the drug discovery process
Cell line development is a major step for examining the efficiency of drug discovery, toxicity and in vitro testing. It reduces time, effort and cost, which minimises the chance of research drugs failing at the clinical trial stage. This stage involves the production of recombinant proteins such as monoclonal antibodies,…
